Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIIMS: Hyper-polarized Carbon 13 MRI in Multiple Sclerosis
NCT07510607Phase 2Recruiting
- Start
- Jun 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hyperpolarized 13C-pyruvate in multiple sclerosis (MS). Started Jun 2026; status: recruiting.
02
Drugs
hyperpolarized 13C-pyruvate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07510607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07510607.